The role of ACKR3 in breast, lung, and brain cancer

Maria Neves, Amos Fumagalli, Jelle van den Bor, Philippe Marin, Martine J. Smit, Federico Mayor*

*Corresponding author for this work

Research output: Contribution to JournalArticleAcademicpeer-review


Recent reports regarding the significance of chemokine receptors in disease have put a spotlight on atypical chemokine receptor 3 (ACKR3). This atypical chemokine receptor is overexpressed in numerous cancer types and has been involved in the modulation of tumor cell proliferation and migration, tumor angiogenesis, or resistance to drugs, thus contributing to cancer progression and metastasis occurrence. Here, we focus on the clinical significance and potential mechanisms underlying the pathologic role of ACKR3 in breast, lung, and brain cancer and discuss its possible relevance as a prognostic factor and potential therapeutic target in these contexts.

Original languageEnglish
Pages (from-to)819-825
Number of pages7
JournalMolecular pharmacology
Issue number6
Publication statusPublished - 1 Dec 2019


Dive into the research topics of 'The role of ACKR3 in breast, lung, and brain cancer'. Together they form a unique fingerprint.

Cite this